Stryker Corporation is a leading medical technology company that specializes in designing, manufacturing, and marketing innovative products and services for healthcare professionals and patients
The company offers a diverse range of medical devices, including surgical equipment, orthopedic implants, neurotechnology, and surgery assistance products. Stryker focuses on advancing healthcare through cutting-edge technology and solutions that enhance patient care, improve surgical outcomes, and streamline hospital operations. With a commitment to innovation and quality, Stryker plays a pivotal role in the medical industry, helping healthcare providers deliver effective treatment and improve the quality of life for patients around the world.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at medical devices & supplies - diversified stocks, starting with Stryker (NYSESYK).
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how medical devices & supplies - diversified stocks fared in Q4, starting with Baxter (NYSEBAX).
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Neogen (NASDAQNEOG) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSEBSX) and the best and worst performers in the medical devices & supplies - diversified industry.
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSEABBV), saying it's “just a gem” and a “winner.” He added, “I can't believe the stock dropped so much.”
Medical technology company Stryker (NYSESYK) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its non-GAAP profit of $4.01 per share was 3.5% above analysts’ consensus estimates.
